Raseglurant

DB05070InvestigationalSmall molecule

ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in... It is developed for the treatment of GERD, migraine and anxiety.

Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in anxiety disorders, gastroesophageal reflux disease (GERD), and migraine and cluster headaches.Curator reviewed
Code names
ADX10059

Resolves to

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Raseglurant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account